APOE polymorphism is associated with risk of severe sepsis in surgical patients

Critical Care Medicine

Volumn 33, Issue 11, 2005, Pages 2521-2526

  Moretti, Eugene W ^a   Morris, Richard W ^a   Podgoreanu, Mihai ^a   Schwinn, Debra A ^a,b,c   Newman, Mark F ^a   Bennett, Ellen ^a   Moulin, Victor G ^a   Mba, Uzo U ^a   Laskowitz, Daniel T ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apolipoprotein E; Association study; Genetic; Human; Inflammation; Polymorphism; Postoperative; Sepsis

Indexed keywords

APOLIPOPROTEIN E;

ADULT; ALLELE; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE SEVERITY; ELECTIVE SURGERY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RACE; RISK ASSESSMENT; SCORING SYSTEM; SEPSIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; SURGICAL PATIENT; UNIVERSITY HOSPITAL;

EID: 27944465278     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000186368.96146.FB     Document Type: Article

References (59)

1. Cohen J: The immunopathogenesis of sepsis. Nature 2002; 420:885-891
2. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-874
4. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
5. van Leeuwen HJ, Heezius EC, Dallinga GM, et al: Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003; 31:1359-1366
6. Fraunberger P, Pilz G, Cremer P, et al: Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock 1998; 10:359-363
7. Gordon BR, Parker TS, Levine DM, et al: Relationship of hypolipidemia to cytokine concentrations and outcomes in critically ill surgical patients. Crit Care Med 2001; 29:1563-1568
8. Fogelman AM: When good cholesterol goes bad. Nat Med 2004; 10:902-903
9. Chenaud C, Merlani PG, Roux-Lombard P, et al: Low apolipoprotein A-I level at intensive care unit admission and systemic inflammatory response syndrome exacerbation. Crit Care Med 2004; 32:632-637
10. Levels JH, Lemaire LC, van den Ende AE, et al: Lipid composition and lipopolysaccharide binding capacity of lipoproteins in plasma and lymph of patients with systemic inflammatory response syndrome and multiple organ failure. Crit Care Med 2003; 31:1647-1653
11. Mahley RW, Rail SC Jr: Apolipoprotein E: Far more than a lipid transport protein. Annu Rev Genomics Hum Genet 2000; 1:507-537
12. Laskowitz DT, Lee DM, Schmechel D, et al: Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000; 41:613-620
13. Guo L, LaDu MJ, Van Eldik LJ: A dual role for apolipoprotein e in neuroinflammation: Anti- and pro-inflammatory activity. J Mol Neurosci 2004; 23:205-212
14. Roselaar SE, Daugherty A: Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39:1740-1743
15. de Bont N, Netea MG, Demacker PN, et al: Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection. J Lipid Res 1999; 40:680-685
16. Alieke GV, De Bont N, Netea MG, et al: Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Med Mycol 2004; 42:341-348
17. Lynch JR, Morgan D, Mance J, et al: Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response. J Neuroimmunol 2001; 114:107-113
18. Lynch JR, Tang W, Wang H, et al: APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003; 278:48529-48533
19. Van Oosten M, Rensen PC, Van Amersfoort ES, et al: Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem 2001; 276:8820-8824
20. Sorbi S, Nacmias B, Piacentini S, et al: ApoE as a prognostic factor for post-traumatic coma. Nat Med 1995; 1:852
21. Friedman G, Froom P, Sazbon L, et al: Apolipoprotein E-epsilon4 genotype predicts a poor outcome in survivors of traumatic brain injury. Neurology 1999; 52:244-248
22. Grocott HP, Newman MF, El-Moalem H, et al: Apolipoprotein E genotype differentially influences the proinflammatory and anti-inflammatory response to cardiopulmonary bypass. J Thorac Cardiovasc Surg 2001; 122:622-623
23. Knaus WA, Draper EA, Wagner DP, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
24. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31:545-548
25. Guo SW, Thompson EA: Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics 1992; 48:361-372
26. Good PI. Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypotheses. Second Edition. New York, Springer-Verlag, 2000
27. Majetschak M, Obertacke U, Schade FU, et al: Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol 2002; 9:1205-1211
28. Mira JP, Cariou A, Grall F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282:561-568
29. Fang XM, Schroder S, Hoeft A, et al: Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27:1330-1334
30. Sutherland AM, Walley KR, Russell JA: Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33:638-644
31. Chung TP, Laramie JM, Province M, et al: Functional genomics of critical illness and injury. Crit Care Med 2002; 30(1 Suppl):S51-S57
32. Lowe PR, Galley HF, Abdel-Fattah A, et al: Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31:34-38
33. Peters DL, Barber RC, Flood EM, et al: Methodologic quality and genotyping reproducibility in studies of tumor necrosis factor-308 G→A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit Care Med 2003; 31:1691-1696
34. Texereau J, Pene, F, Chiche JD et al: Importance of hemostatic gene polymorphisms for susceptibility to and outcome of severe sepsis. Crit Care Med 2004; 32(5 Suppl):S313-S319
35. Wang JE: Can single nucleotide polymorphisms in innate immune receptors predict development of septic complications in intensive care unit patients? Crit Care Med 2005; 33:695-696
36. Gibot SA, Cariou A, Drouet L, et al: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30:969-973
37. Avila EM, Holdsworth G, Sasaki N, et al: Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells. J Biol Chem 1982; 257:5900-5909
38. Pepe MG, Curtiss LK: Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol 1986; 136:3716-3723
39. Cuthbert JA, Lipsky PE: Immunoregulation by low density lipoproteins in man. Inhibition of mitogen-induced T lymphocyte proliferation by interference with transferrin metabolism. J Clin Invest 1984; 73:992-1003
40. Terkeltaub RA, Dyer CA, Martin J, et al: Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. J Clin Invest 1991; 87:20-26
41. Grainger DJ, Reckless J, McKilligin E: Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004; 173:6366-6375
42. Lynch JR, Pineda JA, Morgan D, et al: Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann Neurol 2002; 51:113-117
43. Laskowitz DT, Thekdi AD, Thekdi SD, et al: Downregulation of microglial activation by apolipoprotein E and apoE-mimetic peptides. Exp Neurol 2001; 167:74-85
44. Barlage S, Frohlich D, Bottcher A, et al: ApoE-containing high density lipoproteins and phospholipid transfer protein activity increase in patients with a systemic inflammatory response. J Lipid Res 2001; 42:281-290
45. Sullivan PM, Mezdour H, Aratani Y, et al: Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 1997; 272:17972-17980
46. Drabe N, Zund G, Grunenfelder J, et al: Genetic predisposition in patients undergoing cardiopulmonary bypass surgery is associated with an increase of inflammatory cytokines. Eur J Cardiothorac Surg 2001; 20:609-613
47. Newman MF, Grocott HP, Mathew JP, et al: Report of the substudy assessing the impact of neurocognitive function on quality of life 5 years after cardiac surgery. Stroke 2001; 32:2874-2881
48. Horsburgh K, McCarron MO, White F, et al: The role of apolipoprotein E in Alzheimer's disease, acute brain injury and cerebrovascular disease: Evidence of common mechanisms and utility of animal models. Neurobiol Aging 2000; 21:245-255
49. Laskowitz DT, Horsburgh K, Roses AD: Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998; 18:465-471
50. Egensperger R, Kosel S, von Eitzen U, et al: Microglial activation in Alzheimer disease: Association with APOE genotype. Brain Pathol 1998; 8:439-447
51. Wozniak MA, Faragher EB, Todd JA, et al: Does apolipoprotein E polymorphism influence susceptibility to malaria? J Med Genet 2003; 40:348-351
52. Lin WR, Wozniak MA, Esiri MM, et al: Herpes simplex encephalitis: Involvement of apolipoprotein E genotype. J Neurol Neurosurg Psychiatry 2001; 70:117-119
53. Itzhaki RF, Lin WR, Wilcock GK, et al: HSV-1 and risk of Alzheimer's disease. Lancet 1998; 352:238
54. Wozniak MA, Itzhaki RF, Faragher EB, et al: Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology 2002; 36:456-463
55. Mamotte CD, Sturm M, Foo JI, et al: Comparison of the LDL-receptor binding of VLDL and LDL from apoE4 and apoE3 homozygotes. Am J Physiol 1999; 276:E553-E557
56. Bohnet K, Pillot T, Visvikis S, et al: Apolipoprotein (apo) E genotype and apoE concentration determine binding of normal very low density lipoproteins to HepG2 cell surface receptors. J Lipid Res 1996; 37:1316-1324
57. Wichmann MW, Inthorn D, Andress HJ, et al: Incidence and mortality of severe sepsis in surgical intensive care patients: The influence of patient gender on disease process and outcome. Intensive Care Med 2000; 26:167-172
58. Cardon LR, Palmer LJ: Population stratification and spurious allelic association. Lancet 2003; 361:598-604
59. Tang H, Quertermous T, Rodriguez B, et al: Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005; 76:268-275